X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 54 filers reported holding X4 PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $1,338,216 | -7.7% | 1,347,650 | +58.9% | 0.06% | -6.7% |
Q3 2022 | $1,450,000 | +77.3% | 847,879 | 0.0% | 0.06% | +50.0% |
Q2 2022 | $818,000 | -44.9% | 847,879 | 0.0% | 0.04% | -32.2% |
Q1 2022 | $1,484,000 | -23.6% | 847,879 | 0.0% | 0.06% | -15.7% |
Q4 2021 | $1,942,000 | -56.7% | 847,879 | 0.0% | 0.07% | -60.0% |
Q3 2021 | $4,485,000 | -18.6% | 847,879 | 0.0% | 0.18% | -15.5% |
Q2 2021 | $5,511,000 | -41.4% | 847,879 | -22.3% | 0.21% | -41.2% |
Q1 2021 | $9,398,000 | +84.3% | 1,091,579 | +37.7% | 0.35% | +75.1% |
Q4 2020 | $5,098,000 | -5.0% | 792,892 | 0.0% | 0.20% | -31.2% |
Q3 2020 | $5,368,000 | -43.0% | 792,892 | -21.6% | 0.29% | -49.7% |
Q2 2020 | $9,422,000 | -19.6% | 1,010,892 | -13.7% | 0.58% | -46.8% |
Q1 2020 | $11,717,000 | -4.1% | 1,171,728 | +2.6% | 1.09% | +17.9% |
Q4 2019 | $12,219,000 | +62.0% | 1,141,974 | +92.4% | 0.93% | +16.8% |
Q3 2019 | $7,543,000 | -13.4% | 593,474 | +2.2% | 0.79% | -16.6% |
Q2 2019 | $8,708,000 | – | 580,500 | – | 0.95% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Polaris Venture Management Co. V, L.L.C. | 311,492 | $2,109,000 | 3.48% |
SV Health Investors, LLC | 311,490 | $2,109,000 | 1.07% |
Bain Capital Life Sciences Investors, LLC | 1,648,485 | $11,160,000 | 1.04% |
New Leaf Venture Partners, L.L.C. | 335,000 | $2,268,000 | 0.91% |
Ikarian Capital, LLC | 724,680 | $4,907,000 | 0.36% |
BVF INC/IL | 792,892 | $5,368,000 | 0.29% |
Opaleye Management Inc. | 75,000 | $508,000 | 0.10% |
Orbimed Advisors | 1,086,493 | $7,356,000 | 0.09% |
RA Capital Management | 559,494 | $3,788,000 | 0.07% |
Bleichroeder LP | 35,730 | $242,000 | 0.04% |